MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,112 INR | +1.00% |
|
-3.11% | +6.51% |
| May. 16 | Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024 | |
| May. 16 | Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4 | MT |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 837,588 | - | - |
| Enterprise Value (EV) 1 | 921,654 | 785,450 | 770,789 |
| P/E ratio | 48.3 x | 37.7 x | 32 x |
| Yield | 0.33% | 0.27% | 0.54% |
| Capitalization / Revenue | 8.92 x | 7.21 x | 6.36 x |
| EV / Revenue | 8.92 x | 6.76 x | 5.85 x |
| EV / EBITDA | 36.4 x | 26.5 x | 22.5 x |
| EV / FCF | 54.6 x | 42.3 x | 34.7 x |
| FCF Yield | 1.83% | 2.36% | 2.88% |
| Price to Book | 9.06 x | 7.22 x | 6 x |
| Nbr of stocks (in thousands) | 400,635 | - | - |
| Reference price 2 | 2,091 | 2,091 | 2,091 |
| Announcement Date | 5/15/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 87,494 | 103,348 | 116,107 | 131,721 |
| EBITDA 1 | - | 19,006 | 25,351 | 29,627 | 34,327 |
| EBIT 1 | - | 15,747 | 21,368 | 25,464 | 29,833 |
| Operating Margin | - | 18% | 20.68% | 21.93% | 22.65% |
| Earnings before Tax (EBT) 1 | - | 16,712 | 23,994 | 28,092 | 32,911 |
| Net income 1 | 14,335 | 12,819 | 19,129 | 22,215 | 26,156 |
| Net margin | - | 14.65% | 18.51% | 19.13% | 19.86% |
| EPS 2 | 35.78 | 32.00 | 47.68 | 55.42 | 65.26 |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 18,554 | 22,230 |
| FCF margin | - | 11.71% | 14.44% | 15.98% | 16.88% |
| FCF Conversion (EBITDA) | - | 53.89% | 59.69% | 62.63% | 64.76% |
| FCF Conversion (Net income) | - | 79.91% | 81.35% | 83.52% | 84.99% |
| Dividend per Share 2 | - | - | 6.850 | 5.625 | 11.22 |
| Announcement Date | 8/1/22 | 5/30/23 | 5/15/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 25,786 | 26,998 | 24,214 | 24,228 |
| EBITDA 1 | 6,548 | 6,987 | 5,822 | 5,585 |
| EBIT 1 | 5,675 | 5,706 | 4,347 | 4,155 |
| Operating Margin | 22.01% | 21.13% | 17.95% | 17.15% |
| Earnings before Tax (EBT) 1 | 6,245 | 6,229 | 4,984 | 4,776 |
| Net income 1 | 4,869 | 5,176 | 4,194 | 3,823 |
| Net margin | 18.88% | 19.17% | 17.32% | 15.78% |
| EPS 2 | 12.14 | 11.00 | 9.867 | 9.350 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/2/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 25,253 | 52,138 | 66,799 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 10,243 | 14,885 | 18,554 | 22,230 |
| ROE (net income / shareholders' equity) | - | 18.9% | 21.3% | 21.5% | 20.7% |
| ROA (Net income/ Total Assets) | - | 13.6% | 17.4% | 18.8% | 18.2% |
| Assets 1 | - | 94,317 | 105,403 | 117,913 | 143,627 |
| Book Value Per Share 2 | - | 186.0 | 231.0 | 290.0 | 348.0 |
| Cash Flow per Share 2 | - | 45.30 | 54.90 | 67.60 | 75.60 |
| Capex 1 | - | 7,890 | 4,882 | 4,936 | 5,232 |
| Capex / Sales | - | 9.02% | 4.73% | 4.25% | 3.97% |
| Announcement Date | 8/1/22 | 5/30/23 | 5/15/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,091
INR
Average target price
2,209
INR
Spread / Average Target
+5.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.51% | 10.05B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- MANKIND Stock
- Financials Mankind Pharma Limited
